Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study phase II to determinate the efficacy of sunitinib in patients with renal cells carcinoma metastasic or locally avanced in patients not candidates to curative previous nefrectomy

Next Previous
Trial Profile

Study phase II to determinate the efficacy of sunitinib in patients with renal cells carcinoma metastasic or locally avanced in patients not candidates to curative previous nefrectomy

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Oct 2015

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Renal cancer
  • Focus Therapeutic Use

Most Recent Events

  • 05 Mar 2010 Results of an analysis which aims to identify genetic markers of response and adverse effects of sunitinib were presented at ASCO 2010 Genitourinary Cancers Symposium.
  • 19 May 2008 New trial record.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top